Table 2.
Overview of RGC differentiation protocols from hPSCs published in the past five years (2020–2025)
| Cell type | Culture format | Isolation/enrichment Method | Percentage of RGCs | Total protocol length | References |
|---|---|---|---|---|---|
|
hiPSC • keratinocytes or blood cells- derived |
2D adherent culture | None |
Flow: • 87% POU4F+ • 93% SNCG+ • 22.5% RBPMS+ • 85.5% CD90/THY1+ |
36 days | [47] |
|
hiPSC: • CHOPWT8 • CHOPWT9 • CHOPWT10 |
2D adherent culture | MACS using Thy1.2 microbeads |
Flow (before MACS): • 58% THY1+ • 84% POU4F2+ • 12% RBPMS+ Immunocytochemistry: • 95% POU4F1+ (with MACS) |
35 days | [42] |
| hiPSC | 2D adherent culture | None |
Varies between hiPSC-derived RGCs from different patients Flow: • 49.5–87% POU4F+ • 6–93% SNCG+ • 2.3–46% RBPMS+ • 42–91%CD90/THY1+ |
36 days | [60] |
|
hiPSC • SIX6 risk allele • Healthy control |
2D adherent culture of neural rosettes to RGCs | None |
scRNA seq: • 11.6% mature RGC (58% on retinal lineage; 20% of those in mature RGC stage) |
39 days | [29] |
|
hiPSC • MT-ND4 mutation • Healthy control |
3D embryoid bodies and neurospheres + 2D adherent culture of plated neurospheres |
None | Not stated | 27 days for embryoid bodies, neurosphere generation + 18 days for neurosphere plating to neurite outgrowth | [98] |
|
hiPSC • healthy control; fibroblast- and Müller glia-derived |
3D retinal organoids + 2D adherent culture of dissociated, enriched cells |
• Dissociation of retinal organoids • MACS using human THY1 antibody |
Flow: • 60% THY1⁺ cells before sorting (dissociated culture) • 78% THY1⁺ with MACS enrichment |
56 days for retinal organoid generation + 7 days for RGC adherent culture | [43] |
|
hESC: • H1 |
3D retinal organoids + 2D adherent culture of dissociated cells | Dissociation of retinal organoids |
Immunocytochemistry: • 50% ATOH7+ • 30% SNCG+ • 30% ISL1+ • 50% HuC/D+ |
28 days for retinal organoid generation + 10 days for RGC adherent culture | [24] |
|
hiPSC • TLHD2 • 201B7 |
3D retinal organoids + 2D adherent culture of dissociated, enriched cells |
• Dissociation of retinal organoids • Two-step immunopanning |
Not stated |
55–65 days for retinal organoid generation + 3–5 days for RGC adherent culture |
[93] |
|
hiPSCs • corneal keratocytes-derived |
3D retinal organoids + 2D adherent culture of dissociated cells | Dissociation of retinal organoids | Not stated | 30 days for retinal organoid generation | [97] |
|
hPSC: • OPTN(E50K) mutation |
3D retinal organoids + 2D adherent culture of dissociated, enriched cells |
• Dissociation of retinal organoids • MACS using Thy1.2 |
Immunocytochemistry: • 20–35% POU4F+ • 15–30% ISL1+ |
45 days for retinal organoid generation + up to 28 days for RGC adherent culture | [99] |
|
hiPSC: • fibroblast-derived |
3D retinal organoids + 2D adherent culture of retinal organoids | • None |
scRNA-seq: 17% RGCs (based on the expression of POU4F2, ISL1, RBPMS, SNCG, GAP43, NEFL/M, ELAVL4, EOMES, and DCX) |
35 days for retinal organoid generation + 14 days for retinal organoid adherent culture | [70] |
|
hiPSC • MT-ND4 mutation • Healthy control |
3D retinal organoids + 2D adherent culture of retinal organoids | • None | Not stated | 35 days for retinal organoid generation + 17 days for retinal organoid adherent culture | [100] |
|
hiPSC: • IMR90.4 • GM23720 hESC • WA09 |
2D adherent culture Genome-integrated transcription factors: NGN2, ATOH7, ISL1, POU4F2 |
• Clonal selection with zeocin |
Immunocytochemistry: 88–94% POU4F2+ (tdTomato+) |
6–7 days | [86] |
|
hiPSC: • 297-1 hESC: • POU4F2-driven mCherry H7-A81 |
2D adherent culture Lentiviral delivery of transcription factors: NGN2 |
• Selection with puromycin |
Immunocytochemistry: 14–20% POU4F1+ |
7 days | [84] |
|
hiPSC: • NTUH-iPSC-02-02 • NTUH-iPSC-01–05 |
2D adherent culture Lentiviral delivery of transcription factors: ATOH7, POU4F2, and SOX4 |
• Selection with puromycin + zeocin |
Immunocytochemistry: • 89.5% POU4F1+ • 94.1% ISL1+ 85.3% POU4F1+/ISL1+ |
15–20 days | [85] |